Featured Research

from universities, journals, and other organizations

Early HIV antiviral treatment found to be cost-effective in South Africa, India

Date:
October 30, 2013
Source:
Massachusetts General Hospital
Summary:
"Treatment as prevention" -- early initiation of antiretroviral therapy for HIV-infected individuals with uninfected sexual partners to prevent viral transmission -- appears to make economic sense, along with meeting its clinical goals of helping infected patients stay healthy and reducing transmission.

"Treatment as prevention" -- early initiation of antiretroviral therapy (ART) for HIV-infected individuals with uninfected sexual partners to prevent viral transmission -- appears to make economic sense, along with meeting its clinical goals of helping infected patients stay healthy and reducing transmission. A model-based analysis of data from an important clinical trial projected that early ART for such patients in both South Africa and India would be very cost-effective over the lifetime of patients. In fact, early ART in South Africa would actually save money during the first five years. The report appears in the October 31 New England Journal of Medicine.

"By demonstrating that early HIV therapy not only has long-term clinical benefits to individuals but also provides excellent economic value in both low- and middle-income countries, this study provides a critical answer to an urgent policy question," says Rochelle Walensky, MD, MPH, of the Massachusetts General Hospital (MGH) Division of Infectious Disease, corresponding author of the NEJM report. "In short, early ART is a 'triple winner': HIV-infected patients live healthier lives, their partners are protected from HIV, and the investment is superb."

In 2011 the HIV Prevention Trials Network -- an international research collaborative -- published results of a trial showing that treatment as prevention dramatically reduced the risks of viral transmission and also substantially cut the time to AIDS-related events and infections like tuberculosis in the HIV-infected patients. Called HPTN 052 and conducted at sites in nine countries, that trial was led by Myron Cohen, MD, of the University of North Carolina at Chapel Hill, and subsequently was named the 2011 Breakthrough of the Year by the journal Science. In the current National Institute of Allergy and Infectious Disease (NIAID)-supported study, the researchers worked in collaboration with the HPTN 052 trial team to analyze the trial data -- focusing on sites in India and South Africa, countries with the world's highest rates of HIV infection -- to determine whether those clinical benefits were worth the costs of ART on both short- and long-term bases.

HPTN 052 participants in the early-ART group started treatment at CD4 T cells -- a measure of immune system function -- between 350 and 550, while the control group did not start therapy until their CD4 cells dropped below 250, which was in line with World Health Organization treatment guidelines at the time. In their current analysis, the researchers used a mathematical model simulating HIV treatment and transmission and its associated health and economic outcomes to make projections for two years (the time period covered by HPTN 052), five years, and the expected lifetime of the infected participants.

The results indicated that, during the first five years, 93 percent of patients receiving early ART would survive, compared with 83 percent of those whose treatment was delayed. Life expectancy for the early-treatment group was almost 16 years, compared with nearly 14 years for the delayed treatment group. During the first five years, the potential costs of infections that were prevented by early treatment in South Africa -- particularly tuberculosis -- would outweigh the costs of ART medications, indicating that the strategy actually would save overall costs. While this was not the case for India, where costs of care for opportunistic infections are less, early ART in that country was projected to be cost-effective, according to established standards. Across patient lifetimes, early ART was determined to be very cost effective in both countries. Most of the clinical benefits were seen in the infected patients -- fewer illnesses and deaths -- and there were also added clinical and economic benefits from reducing HIV transmission.

"The reason early ART doesn't save money in the long term is actually due to its success," explains Walensky, who is a professor of Medicine at Harvard Medical School. "Patients will live much longer and take these effective medications for many years. Now that we know that early ART not only improves clinical and prevention outcomes but also is a great investment, we need to redouble international efforts to provide ART to any HIV-infected person who can benefit from it."

"Some people have questioned whether providing early ART to all who need it would be feasible in resource-limited countries," adds Kenneth Freedberg, MD, MSc, director of the MGH Medical Practice Evaluation Center, professor of Medicine at Harvard Medical School and senior author. "We've shown that in countries like South Africa, where it actually saves money in the short-term, the answer is 'yes.' We believe that continued international public and private partnerships can make this true in other countries as well. With this kind of investment, we foresee dramatic decreases in infections and illness that could save millions of lives over the next decade."


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rochelle P. Walensky, Eric L. Ross, Nagalingeswaran Kumarasamy, Robin Wood, Farzad Noubary, A. David Paltiel, Yoriko M. Nakamura, Sheela V. Godbole, Ravindre Panchia, Ian Sanne, Milton C. Weinstein, Elena Losina, Kenneth H. Mayer, Ying Q. Chen, Lei Wang, Marybeth McCauley, Theresa Gamble, George R. Seage, Myron S. Cohen, Kenneth A. Freedberg. Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. New England Journal of Medicine, 2013; 369 (18): 1715 DOI: 10.1056/NEJMsa1214720

Cite This Page:

Massachusetts General Hospital. "Early HIV antiviral treatment found to be cost-effective in South Africa, India." ScienceDaily. ScienceDaily, 30 October 2013. <www.sciencedaily.com/releases/2013/10/131030185710.htm>.
Massachusetts General Hospital. (2013, October 30). Early HIV antiviral treatment found to be cost-effective in South Africa, India. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2013/10/131030185710.htm
Massachusetts General Hospital. "Early HIV antiviral treatment found to be cost-effective in South Africa, India." ScienceDaily. www.sciencedaily.com/releases/2013/10/131030185710.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins